Table 1.
Summary table of trials included in meta-analysis
| Trial | Population | Median age | Size | Stage | Dose (mg/m2) | Total number of doses | Concomitant chemotherapy | Control chemotherapy |
|---|---|---|---|---|---|---|---|---|
| Amadori 2013 | APML excluded | 67 | 472 | Induction and consolidation | 6 (induction), 3 (consolidation) | 2 (induction), 2 (consolidation) | MICE (induction), ICE (consolidation) | Same concomitant chemotherapy as in GO arm |
| Burnett 2011 (induction randomisation) | As above | 49 | 1113 | Induction | 3 | 1 | DA/ADE/FLAG-IDA | As above |
| Burnett 2011 (consolidation randomisation) | As above | 46 | 948 | Consolidation | 3 | 1 | MACE/Ara-C | As above |
| Burnett 2012 (intensive trial) | AML and high-risk MDS | 67 | 1115 | Induction | 3 | 1 | DA or d-Clo at induction (2–3 courses), Aza maintenance | As above |
| Burnett 2012 (low-intensity trial) | AML, high-risk MDS | 75 | 495 | Low intensity | Flat dose of 5 | 4 | Low-dose Ara-C 20 mg s/c injection | As above |
| Castaigne 2012 | Primary AML | 62 | 280 | Induction and consolidation | 3 | 3 (induction), 2 (consolidation) | DA (1–2 courses at induction); two courses of DA as consolidation | As above |
| Delaunay 2011 ASH | Intermediate-karyotype AML | 50 | 254 | Induction and consolidation | 6 | 2 | DA induction and MidAC intensive consolidation | As above |
| Fernandez 2011 | APML excluded | 48 | 270 | Consolidation | 6 | 1 | None | None |
| Gamis 2013 ASH | Primary AML | 9.9 | 1070 | Induction and consolidation | 3 | 1 (induction), 1 (consolidation) | ADE at induction and mitoxantrone/Ara-C at second consolidation | Same concomitant chemotherapy as in GO arm |
| Hasle 2012 | Standard/high-risk disease in CR1 post-consolidation | Not reported | 120 | Maintenance | 5 | 2 | None | None |
| Lowenberg 2010 | APML excluded | 67 | 232 | Maintenance | 6 | 3 | None | None |
| Petersdorf 2013 (induction randomisation) | As above | 47 | 595 | Induction | 6 | 1 | DA (45 mg/m2 daunorubicin) | DA (60 mg/m2 daunorubicin) |
| Petersdorf 2013 (maintenance randomisation) | As above | Not reported | 174 | Maintenance | 5 | 3 | None | None |